Aspire Biopharma Holdings Inc (ASBP)

$6.03 +0.06 (1.01%)
Market Cap 7.73M
Revenue (ttm) 10,000.00
Net Income (ttm) -24.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -244,800.00%
Debt to Equity Ratio 0.00
Volume 22,900
Avg Vol 621,690
Day's Range N/A - N/A
Shares Out 1.30M
Stochastic %K 63%
Beta 0.15
Analysts Strong Buy
Price Target N/A

Company Profile

Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, such as melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semag...

Industry: Biotechnology
Sector: Healthcare
Phone: 908 987 3002
Address:
23150 Fashion Drive, Suite 232, Estero, United States
Arnie_510
Arnie_510 Jul. 15 at 4:01 AM
$ASBP @Evilalchemist I wonder if there are any lawsuits brewing behind the scenes? Lot of investors took a beating on this.
0 · Reply
Evilalchemist
Evilalchemist Jul. 15 at 1:02 AM
$ASBP trash save money don’t buy this
0 · Reply
Arnie_510
Arnie_510 Jul. 14 at 10:05 PM
$ASBP @Leo70o Says it’s run by nothing but a bunch of thieving scumbags. 👇
0 · Reply
LuigiV_
LuigiV_ Jul. 14 at 7:34 PM
$NIPG $ASBP $HBIO $JEM fac
0 · Reply
Arnie_510
Arnie_510 Jul. 14 at 1:55 PM
$ASBP You’re not alone @Leo70o got taken to the cleaners.
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:11 PM
$ASBP Kevin ad Kraig lie through their teeth no moral compass what so ever
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:10 PM
$ASBP they have no break thru it’s the same as chewing up aspirin that’s why they aren’t giving any news on FDA they were supposed to have filed a 505 already and now are saying maybe in 2027
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:09 PM
$ASBP one of the top worst stocks of 2026 bunch of crooks stole millions from everyday traders and investors
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 10:51 AM
$ASBP they are going to drive the stock down again and exercise warrants at floor price dilute and split again
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 10:50 AM
$ASBP no intentions of filing 505 until 2027 according to investor relations. Still have not even set a date for the day human trial. Smoke and mirrors piece of shit stick lost 45+k on this turd
1 · Reply
Latest News on ASBP
Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

Jun 24, 2026, 8:30 AM EDT - 20 days ago

Aspire Biopharma's BUZZ BOMB(TM) Launches on Amazon, Introducing Next-Generation Caffeine Stick Packs

TM

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

Jun 17, 2026, 10:57 AM EDT - 27 days ago

Aspire Biopharma to Present at the Life Sciences Investor Forum on June 25th

Aspire Biopharma Holdings Inc trading resumes

2026-06-12T18:20:26.000Z - 4 weeks ago

Aspire Biopharma Holdings Inc trading resumes

Aspire Biopharma Holdings Inc trading halted, volatility trading pause

2026-06-12T18:10:38.000Z - 4 weeks ago

Aspire Biopharma Holdings Inc trading halted, volatility trading pause

Aspire Biopharma signs definitive SPA to acquire Dura Driver Control Systems

2026-06-12T12:37:16.000Z - 4 weeks ago

Aspire Biopharma signs definitive SPA to acquire Dura Driver Control Systems

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Jun 12, 2026, 8:30 AM EDT - 4 weeks ago

Aspire Biopharma Announces Signing of Definitive Share Purchase Agreement to Acquire Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma issues letter to shareholders

2026-05-28T15:44:39.000Z - 6 weeks ago

Aspire Biopharma issues letter to shareholders

Aspire Biopharma Issues Shareholder Letter

May 28, 2026, 8:30 AM EDT - 6 weeks ago

Aspire Biopharma Issues Shareholder Letter

Aspire Biopharma’s Buzz Bomb partners with EoS Fitness

2026-05-27T13:26:22.000Z - 6 weeks ago

Aspire Biopharma’s Buzz Bomb partners with EoS Fitness

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

May 27, 2026, 8:30 AM EDT - 6 weeks ago

Aspire Biopharma's BUZZ BOMBTM Partners with EoS Fitness to Empower High-Performance Lifestyles for Millions of Members

Aspire Biopharma Holdings Inc trading halted, news pending

2026-05-08T23:50:15.000Z - 2 months ago

Aspire Biopharma Holdings Inc trading halted, news pending

Aspire Biopharma to effect 1-for-30 reverse stock split

2026-05-07T17:59:49.000Z - 2 months ago

Aspire Biopharma to effect 1-for-30 reverse stock split

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

May 7, 2026, 11:00 AM EDT - 2 months ago

Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio

Aspire Biopharma announces $5M share repurchase plan

2026-04-27T12:40:32.000Z - 2 months ago

Aspire Biopharma announces $5M share repurchase plan

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Apr 27, 2026, 8:30 AM EDT - 2 months ago

Aspire Biopharma Announces $5.0 Million Share Repurchase Program

Aspire Biopharma closes final tranche of $21M private placement

2026-04-20T14:15:12.000Z - 3 months ago

Aspire Biopharma closes final tranche of $21M private placement

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Apr 20, 2026, 8:30 AM EDT - 3 months ago

Aspire Biopharma Announces Closing of Second and Final Tranche of $21 Million Private Placement by Select Investors; Secures Commitment Letter for $22.5M Credit Facility to Fund the DCS Acquisition

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

2026-04-17T12:15:44.000Z - 3 months ago

Buzz Bomb brand ambassador to attempt fastest 100-mile treadmill run

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Apr 17, 2026, 8:00 AM EDT - 3 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company's Brand Ambassador, Ashley Paulson, to Attempt Fastest 100-Mile Treadmill Run at 2026 Boston Marathon Expo

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

2026-04-16T12:48:21.000Z - 3 months ago

Aspire Biopharma enters LOI to acquire Dura Driver Control Systems for $30M

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Apr 16, 2026, 8:30 AM EDT - 3 months ago

Aspire Biopharma Has Entered Into a Letter of Intent to Acquire a Leading Global Automotive Supplier With a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

2026-04-15T12:22:20.000Z - 3 months ago

Aspire Biopharma subsidiary announce sales, marketing agreement with Interwest

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Apr 15, 2026, 8:00 AM EDT - 3 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

2026-03-19T12:57:13.000Z - 4 months ago

Aspire Biopharma subsidiary signs retail distribution agreement with TruLife

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Mar 19, 2026, 8:00 AM EDT - 4 months ago

Aspire Biopharma's Subsidiary Announces Agreement with TruLife Distribution to Drive National Retail Expansion

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Mar 17, 2026, 8:30 AM EDT - 4 months ago

Aspire Biopharma's Subsidiary, Buzz Bomb Caffeine Company, Appoints John Choe as Western Sales Director

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Mar 12, 2026, 8:00 AM EDT - 4 months ago

Aspire Biopharma's Subsidiary to Feature BUZZ BOMB(TM) at The Health & Fitness Show 2026

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

2026-03-10T12:51:37.000Z - 4 months ago

Aspire Biopharma launches BUZZ BOMB Covenience Store Pack

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Mar 10, 2026, 8:30 AM EDT - 4 months ago

Aspire Biopharma's BUZZ BOMB(TM) Disrupts Energy Category with New Convenience Store Pack

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

2026-03-03T13:30:58.000Z - 4 months ago

Aspire Biopharma, Microsize partner for sublingual alprazolam formulation

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Mar 3, 2026, 8:00 AM EST - 4 months ago

Aspire Biopharma Partners with Microsize to Develop Rapid-delivery Sublingual Powder Formulation of Alprazolam for Faster Anxiety Relief

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

2026-02-25T14:02:56.000Z - 4 months ago

Aspire Biopharma’s Buzz Bomb announces expansion of social media footprint

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Feb 25, 2026, 8:30 AM EST - 4 months ago

Aspire Biopharma's Buzz Bomb(TM) Caffeine Company Achieves Record Social Media Growth and Sales Surge Following World-Record Marathon Sponsorship

Aspire Biopharma regains compliance with Nasdaq listing requirements

2026-02-20T13:05:16.000Z - 5 months ago

Aspire Biopharma regains compliance with Nasdaq listing requirements

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Feb 20, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Regains Full Compliance with Nasdaq Listing Requirements

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Feb 19, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma's Buzz Bomb Caffeine Company Names ChicExecs as Public Relations Agency of Record

Aspire Biopharma files to sell 159.1M shares of common stock for holders

2026-02-17T21:25:29.000Z - 5 months ago

Aspire Biopharma files to sell 159.1M shares of common stock for holders

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Feb 17, 2026, 8:30 AM EST - 5 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Meclizine (Generic Dramamine(R))

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Feb 13, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Feb 12, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Files Provisional Patent Application for a Fast-Acting Sublingual Powder Formulation of Ondansetron (Generic Zofran(R))

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Feb 11, 2026, 7:45 AM EST - 5 months ago

Aspire Biopharma Announces $21 Million Private Placement by Select Investors, Strengthening Balance Sheet, Capital Position, and Fortifying Shareholder Equity to Meet Nasdaq Requirements

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Feb 10, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Feb 5, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, to Showcase BUZZ BOMB(TM) Caffeine and its Innovative Sublingual Delivery Technology at The Sports & Active Nutrition Summit

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Feb 3, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma's Wholly Owned Subsidiary, Buzz Bomb Caffeine Company, Partners with Blue Shark Beverages to Expand Southern California Distribution

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Jan 29, 2026, 8:00 AM EST - 5 months ago

Aspire Biopharma Secures Agreement with Microsize for Development of Novel Sublingual Aspirin

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Jan 27, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Powder Formulation of Clopidogrel (Generic Plavix(R)) to Address Gastric Bleeding Risks

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Jan 22, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Jan 21, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma's Unveils Bold New Era for BUZZ BOMB(TM) Caffeine with Dynamic Website and Packaging Redesign

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Jan 20, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Files Provisional Patent Application for Industry-First Sublingual Formulation of Alprazolam - Generic Xanax(R) - for Rapid Anxiety Relief

Aspire Biopharma Announces Reverse Stock Split

Jan 14, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Announces Reverse Stock Split

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Jan 7, 2026, 8:00 AM EST - 6 months ago

Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Dec 18, 2025, 8:30 AM EST - 7 months ago

Aspire Biopharma Welcomes Elite Ultra-Runner Ashley Paulson as Global Brand Ambassador for BUZZ BOMB(R) Caffeine

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Dec 12, 2025, 5:00 PM EST - 7 months ago

Aspire Biopharma Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements

Aspire Biopharma Provides Q3 2025 Business Update

Dec 4, 2025, 9:00 AM EST - 7 months ago

Aspire Biopharma Provides Q3 2025 Business Update

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Dec 2, 2025, 9:00 AM EST - 8 months ago

Aspire Biopharma Submits Pre-IND Meeting Request and Briefing Package to U.S. FDA for Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Nov 26, 2025, 9:00 AM EST - 8 months ago

Aspire BioPharma Welcomes Dr. Mark J. Jaroszeski as New Scientific Team Member

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Nov 6, 2025, 9:00 AM EST - 8 months ago

Aspire Biopharma Engages with Global Pharmaceutical Leaders at CPHI Frankfurt to Advance Partnership Discussions for its Sublingual High-Dose Aspirin

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Oct 6, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Holdings, Inc. Announces Filing of Omnibus Patent Application for Its Innovative Sublingual Drug Delivery Platform

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Oct 3, 2025, 11:30 AM EDT - 10 months ago

Aspire Biopharma to Present at Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference - October 8-9, 2025

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Oct 1, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Announces Milestone Roadmap Targeting H2 2025 FDA Submission for Sublingual Aspirin and Key 2026 Milestones for Needle-Free Semaglutide (Diabetes, Weight Management) and more-rapid ED medication

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Sep 17, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Engages Well-Known Athletes and Influencers to Accelerate Consumer Awareness and Sales of its BUZZ BOMB(TM) Sublingual Caffeine Pre-Workout Product

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Sep 16, 2025, 8:30 AM EDT - 10 months ago

Aspire Biopharma Announces Initial Production Order of Two Million Servings (100,000 20-packs) of BUZZ BOMB(TM) Pre-Workout Supplement

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Sep 3, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aug 18, 2025, 8:30 AM EDT - 11 months ago

Aspire Biopharma Announces Positive Top-Line Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aug 14, 2025, 8:00 AM EDT - 11 months ago

Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 20

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aug 13, 2025, 9:10 AM EDT - 11 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Jul 31, 2025, 8:30 AM EDT - 1 year ago

Aspire Biopharma Holdings, Inc. Unveils E-commerce Platform, Launches with its BUZZ BOMB Pre-Workout Supplement

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Jul 30, 2025, 7:45 PM EDT - 1 year ago

Aspire Biopharma Holdings, Inc. Announces CEO Transition

Arnie_510
Arnie_510 Jul. 15 at 4:01 AM
$ASBP @Evilalchemist I wonder if there are any lawsuits brewing behind the scenes? Lot of investors took a beating on this.
0 · Reply
Evilalchemist
Evilalchemist Jul. 15 at 1:02 AM
$ASBP trash save money don’t buy this
0 · Reply
Arnie_510
Arnie_510 Jul. 14 at 10:05 PM
$ASBP @Leo70o Says it’s run by nothing but a bunch of thieving scumbags. 👇
0 · Reply
LuigiV_
LuigiV_ Jul. 14 at 7:34 PM
$NIPG $ASBP $HBIO $JEM fac
0 · Reply
Arnie_510
Arnie_510 Jul. 14 at 1:55 PM
$ASBP You’re not alone @Leo70o got taken to the cleaners.
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:11 PM
$ASBP Kevin ad Kraig lie through their teeth no moral compass what so ever
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:10 PM
$ASBP they have no break thru it’s the same as chewing up aspirin that’s why they aren’t giving any news on FDA they were supposed to have filed a 505 already and now are saying maybe in 2027
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 1:09 PM
$ASBP one of the top worst stocks of 2026 bunch of crooks stole millions from everyday traders and investors
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 10:51 AM
$ASBP they are going to drive the stock down again and exercise warrants at floor price dilute and split again
0 · Reply
Evilalchemist
Evilalchemist Jul. 14 at 10:50 AM
$ASBP no intentions of filing 505 until 2027 according to investor relations. Still have not even set a date for the day human trial. Smoke and mirrors piece of shit stick lost 45+k on this turd
1 · Reply
larrythelooper
larrythelooper Jul. 14 at 9:35 AM
$ASBP 🤮💩Please, for Pete’s sake, Stop kidding yourself! This one isn’t going to the 🌕 on a 🚀…Wake Up!!! There’s is No Miracle Cure or Cutting Edge Breakthrough Texhnology. It’s just a Boy and his Plan to separate you from your Hard Earned 💰… Ps. I’m not a Short here. Im just a Bitter Working Stiff that got my 🫏 handed to me by this POS💩 at the end of last year by “Sublingual Asprin”. I hope I can help Save others from the Pain that I still feel every day as I trudge off to work in the real world to try and get back some of my Retirement Plan. Thanks for listening.
0 · Reply
LuigiV_
LuigiV_ Jul. 13 at 6:57 PM
$ASBP $LNZA $DCOY program
0 · Reply
Evilalchemist
Evilalchemist Jul. 10 at 8:40 PM
$ASBP scam central more dilution then reverse split imbound wash repeat
0 · Reply
Arnie_510
Arnie_510 Jul. 10 at 5:54 PM
$ASBP Attention dumbasses: Put the aspirin in your mouth and chew it up.
0 · Reply
Arnie_510
Arnie_510 Jul. 10 at 2:40 PM
$ASBP @Leo70o $25K Bubble Bath He’s not the only one that’s upset!
0 · Reply
ZacksSCR
ZacksSCR Jul. 10 at 2:38 PM
$ASBP OTC Markets Life Sciences Investor Forum Replay: Stephen Quesenberry, General Counsel and Director of Product Development, of Aspire Biopharma with Zacks SCR’s David Bautz, PhD https://buff.ly/oT5Md7T
0 · Reply
Arnie_510
Arnie_510 Jul. 10 at 3:02 AM
$ASBP One last thing! Could @Leo70o be onto something? Read what he posted. “𝘛𝘩𝘪𝘴 𝘤𝘰𝘮𝘱𝘢𝘯𝘺 𝘪𝘴 𝘳𝘶𝘯 𝘣𝘺 𝘯𝘰𝘵𝘩𝘪𝘯𝘨 𝘣𝘶𝘵 𝘢 𝘣𝘶𝘯𝘤𝘩 𝘰𝘧 𝘵𝘩𝘪𝘦𝘷𝘪𝘯𝘨 𝘴𝘤𝘶𝘮𝘣𝘢𝘨𝘴”
0 · Reply
Arnie_510
Arnie_510 Jul. 10 at 2:54 AM
$ASBP One former shareholder said the only thing holding this pile of 💩 together was their ability to enact reverse stock splits. (Two this year!) It’s like free money that buys them time to come up with the next “snake oil“ trick. Ok, I’ll play along with your silent treatment game until tomorrow.
0 · Reply
Arnie_510
Arnie_510 Jul. 10 at 1:33 AM
$ASBP Then there's this dumpster fire. Sublingual aspirin 🤡 BUZZ BOMB 🤡 Auto Parts Acquisition 🤡 Reverse Stock Split 1 🤬 Reverse Stock Split 2 🤬
0 · Reply
Arnie_510
Arnie_510 Jul. 9 at 4:03 PM
$ASBP It’s amazing how investors wake up after being kicked in the balls (screwed) by unsavory companies.
0 · Reply
allnighttom
allnighttom Jul. 9 at 3:26 PM
$ASBP FDA
0 · Reply
Arnie_510
Arnie_510 Jul. 9 at 3:21 PM
$ASBP They want you to take your losses and move on. It pisses them off when duped investors push back. Two reverse stock splits this year alone, benefitting them and not the retail investor. Don’t look for SEC assistance, they’re too busy scolding Martha Stewart types.
0 · Reply